The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death.
Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.
French-speaking patients aged 60 to 90 years,
Patient in the context of Alzheimer's disease * for which imaging after MRI is prescribed as part of the usual diagnostic process,
MMSE score ≥18,
Written informed consent after the patient has been informed,
Patient with an absolute contraindication to 7T MRI
Severe psychiatric pathology not balanced,
Non-degenerative neurological disease (stroke, multiple sclerosis ...),
Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score > 3)